Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, has acquired Biologos LLC, a full-service manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera.
 
Founded in 1976, Biologos provides custom and standard products spanning cell culture media, reagents, enzymes, salts/buffers, and sera, many with customized container, fill, and packaging solutions. Biologos operates from its brand-new 32,000-square-foot cGMP facility just outside Chicago, IL.
 
The partnership with Ampersand will include investments to expand Biologos’ capabilities, product offerings, and geographic reach to support its cell and gene therapy, biopharmaceutical, tissue processing, and animal health customers globally.
 
Biologos CEO Tony Bazarko comments, “This is an exciting time at Biologos as we have experienced impressive growth thanks to our team’s ability to provide high-quality standard and custom biologics solutions for our customers. Ampersand’s deep industry expertise, broad network, and capital resources will enable Biologos to accelerate its growth strategy through the development of new products and its expansion into new markets.”
 
As part of the transaction, Frank Witney, an industry veteran and Ampersand Operating Partner, has been named Chairman of Biologos, with Eric Lev and Mario Reto of Ampersand also appointed as new Board Members.
 
Eric Lev adds, “The investment in Biologos aligns well with Ampersand’s strategy of supporting growth-oriented life science organizations with a history of product innovation and customer excellence. Under Tony’s leadership, we are confident in the team’s ability to continue its strong momentum and look forward to partnering together on this growth journey.”